These data undoubtedly reinforce the view genetically that CD39+CD8+ T cells are most likely a suitable diagnostic indicator for cancer including ESCC and further provide a novel strategy for restoring partially exhausted CD8+ T cells or suppressing CD8+ T cells with regulatory properties by inhibiting CD39. The gene discussed is CD8A; the disease is cancer.